GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Beijing Kawin Technology Share-Holding Co 688687.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

15.86

-0.94%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Beijing Kawin Technology Share-Holding Co

Its shares trade on Shanghai under the ticker 688687.SS. It has been listed since 8 February 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.32bn and net income of CN¥29.6m. At that date it held total assets of CN¥2.79bn and shareholders' equity of CN¥1.71bn.

Beijing Kawin Technology Share-Holding Co., Ltd. provides biotechnology treatment solutions and medicines. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-02-08. The firm's recombinant human interferon α2b and compound glycyrrhizin drugs are applied to treat viral diseases. The firm mainly distributes its products within domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Feb 2021
Employees
681

Leadership

Pay as last reported

  • Mr. Desheng ZhouChairman of the Board, President, since 2008CN¥1.6m
  • Mr. Chongfei HeChief Financial Officer, Vice President, Secretary of the Board, since 2024CN¥1.2m
  • Mr. Zhan WangChief Human Resource Officer
  • Ms. Huan WangExecutive Vice President, DirectorCN¥831,900
  • Mr. Jifeng ShiChief Research Officer, Vice President, Director, since 2024CN¥1.4m
  • Mr. Zhenqiang DuVice PresidentCN¥475,800
  • Mr. Jian TangVice PresidentCN¥2.2m
  • Ms. Xiao XuVice President, since 2024CN¥805,400
  • Mr. Shaoping YinDirector
  • Mr. Chen DuIndependent DirectorCN¥113,400
  • Ms. Manli SunIndependent DirectorCN¥91,200
  • Mr. Jianwei ZhuIndependent DirectorCN¥91,200

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company provides biotechnology treatment solutions and medicines.
  • It distributes products mainly within the domestic market.
  • Recombinant human interferon α2b treats viral diseases.

Weaknesses

  • The firm relies on a single domestic market.
  • Only two specific drug types are mentioned.
  • Employee count is relatively small at 681.

Opportunities

  • Expanding distribution beyond the domestic market.
  • Developing new medicines for viral diseases.
  • Leveraging its IPO status for growth.

Threats

  • Competition in the biotechnology sector.
  • Regulatory changes in the health care industry.
  • Market saturation in the domestic region.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.